KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Shares Issued (2017 - 2024)

Cardlytics (CDLX) has disclosed Shares Issued for 8 consecutive years, with $11000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Shares Issued changed N/A year-over-year to $11000.0, compared with a TTM value of $11000.0 through Sep 2025, down 99.98%, and an annual FY2024 reading of $48.6 million, up 88345.45% over the prior year.
  • Shares Issued was $11000.0 for Q4 2024 at Cardlytics, down from $48.6 million in the prior quarter.
  • Across five years, Shares Issued topped out at $484.7 million in Q1 2021 and bottomed at -$18000.0 in Q4 2022.
  • Average Shares Issued over 5 years is $34.1 million, with a median of $349000.0 recorded in 2021.
  • The sharpest move saw Shares Issued skyrocketed 15312.18% in 2021, then plummeted 108.0% in 2022.
  • Year by year, Shares Issued stood at $3.8 million in 2020, then plummeted by 94.09% to $225000.0 in 2021, then tumbled by 108.0% to -$18000.0 in 2022, then skyrocketed by 344.44% to $44000.0 in 2023, then crashed by 75.0% to $11000.0 in 2024.
  • Business Quant data shows Shares Issued for CDLX at $11000.0 in Q4 2024, $48.6 million in Q1 2024, and $44000.0 in Q3 2023.